What Are the Net Benefits of Single vs. Double Doses of Dabigatran in AFib Patients?
Both single and double doses of dabigatran are superior to warfarin in AFib patients and have similar benefits when considering a weighted efficacy and safety estimate, according to a study published June 11 in the Journal of the American College of Cardiology.
The authors note that, "when comparing the two doses of dabigatran, their net clinical benefit is similar irrespective of whether death is included in the calculation of net benefit. The results are also similar when net benefit is examined using unweighted composite outcomes that include various combinations of major efficacy and safety events."
"These data support a role for both the 110 mg and the 150 mg dose of dabigatran in clinical practice and the approach of tailoring the dose based on individual patient characteristics," they add.
< Back to Listings